Utilising subgroup analysis, the study identified a longer PFS rate in patients receiving first-line EGFR-TKI treatment compared to those undergoing second-line or higher EGFR-TKI treatment among patients with advanced NSCLC with the exon 19 deletion mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.